Free Trial Information
BioCentury | Nov 23, 2009
Clinical News

Apoptone: Interim Phase I/II data

...were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Sep 21, 2009
Financial News

Hollis-Eden financial update

...bid price requirement for continued listing. The company has until March 15 to regain compliance. Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Aug 17, 2009
Company News

Viral Genetics, University of Colorado, University of Vermont cancer news

...CEO of the subsidiary. Previously, Trauger was senior director for infectious disease and cancer at Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Jun 29, 2009
Company News

Hollis-Eden management update

Hollis-Eden Pharmaceuticals Inc. (NASDAQ:HEPH), San Diego, Calif. Business: Endocrine, Autoimmune, Cancer Promoted: James Frincke to president and CEO from CSO; Frincke also becomes a director WIR Staff...
Read More
BioCentury | Apr 6, 2009
Finance

Restructuring watch

...cuts coming from therapeutics R&D; expects to save about $163,000 per month after 1Q09 2/2/09 Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Mar 30, 2009
Company News

Hollis-Eden management update

Hollis-Eden Pharmaceuticals Inc. (NASDAQ:HEPH), San Diego, Calif. Business: Endocrine, Autoimmune, Cancer Transitioned: James Frincke to interim CEO while remaining COO; he replaces Richard Hollis, who was terminated WIR Staff...
Read More
BioCentury | Feb 9, 2009
Company News

Hollis-Eden cancer, gastrointestinal, autoimmune news

...the company had $29 million in cash and a nine-month net loss of $16.6 million. Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Feb 2, 2009
Clinical News

Hollis-Eden preclinical data

...3-kinase / protein kinase B ( PI3K /Akt) pathway, in LNCaP cell lines in vitro. Hollis-Eden...
...Data were presented at the AACR Advances in Prostate Cancer Research conference in San Diego. Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Feb 2, 2009
Clinical News

Hollis-Eden preclinical data

...were presented at a Keystone Symposium on Type II diabetes and insulin resistance in Banff. Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Oct 23, 2008
Cover Story

Suppressing the Suppressors

...II (Japan) Cleveland BioLabs Inc. (NASDAQ:CBLI) Curaxin (CBLC102) Advanced hormone-refractory prostate cancer (HRPC) Phase II Hollis-Eden Pharmaceuticals Inc....
Read More
Items per page:
1 - 10 of 164
BioCentury | Nov 23, 2009
Clinical News

Apoptone: Interim Phase I/II data

...were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Sep 21, 2009
Financial News

Hollis-Eden financial update

...bid price requirement for continued listing. The company has until March 15 to regain compliance. Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Aug 17, 2009
Company News

Viral Genetics, University of Colorado, University of Vermont cancer news

...CEO of the subsidiary. Previously, Trauger was senior director for infectious disease and cancer at Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Jun 29, 2009
Company News

Hollis-Eden management update

Hollis-Eden Pharmaceuticals Inc. (NASDAQ:HEPH), San Diego, Calif. Business: Endocrine, Autoimmune, Cancer Promoted: James Frincke to president and CEO from CSO; Frincke also becomes a director WIR Staff...
Read More
BioCentury | Apr 6, 2009
Finance

Restructuring watch

...cuts coming from therapeutics R&D; expects to save about $163,000 per month after 1Q09 2/2/09 Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Mar 30, 2009
Company News

Hollis-Eden management update

Hollis-Eden Pharmaceuticals Inc. (NASDAQ:HEPH), San Diego, Calif. Business: Endocrine, Autoimmune, Cancer Transitioned: James Frincke to interim CEO while remaining COO; he replaces Richard Hollis, who was terminated WIR Staff...
Read More
BioCentury | Feb 9, 2009
Company News

Hollis-Eden cancer, gastrointestinal, autoimmune news

...the company had $29 million in cash and a nine-month net loss of $16.6 million. Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Feb 2, 2009
Clinical News

Hollis-Eden preclinical data

...3-kinase / protein kinase B ( PI3K /Akt) pathway, in LNCaP cell lines in vitro. Hollis-Eden...
...Data were presented at the AACR Advances in Prostate Cancer Research conference in San Diego. Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Feb 2, 2009
Clinical News

Hollis-Eden preclinical data

...were presented at a Keystone Symposium on Type II diabetes and insulin resistance in Banff. Hollis-Eden Pharmaceuticals Inc....
Read More
BioCentury | Oct 23, 2008
Cover Story

Suppressing the Suppressors

...II (Japan) Cleveland BioLabs Inc. (NASDAQ:CBLI) Curaxin (CBLC102) Advanced hormone-refractory prostate cancer (HRPC) Phase II Hollis-Eden Pharmaceuticals Inc....
Read More
Items per page:
1 - 10 of 164